- Trials with a EudraCT protocol (2,770)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
2,770 result(s) found for: cancer.
Displaying page 19 of 139.
| EudraCT Number: 2010-022674-14 | Sponsor Protocol Number: I5A-MC-JAEM | Start Date*: 2011-02-25 | |||||||||||
| Sponsor Name:Lilly S.A. | |||||||||||||
| Full Title: Estudio en fase 2, abierto, multicéntrico y aleatorizado para evaluar la seguridad y la eficacia de cisplatino y pemetrexed con o sin cixutumumab como tratamiento de primera línea en pacientes con ... | |||||||||||||
| Medical condition: carcinoma de pulmón no microcítico avanzado, de histología no escamosa | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-004618-93 | Sponsor Protocol Number: R120502 | Start Date*: 2017-12-12 | ||||||||||||||||
| Sponsor Name:University of Manchester | ||||||||||||||||||
| Full Title: Evaluation of the safety of CEdiranib in the prevention of Bowel perforation in platinum-resistant Ovarian Cancer | ||||||||||||||||||
| Medical condition: Platinum-Resistant Ovarian Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-007152-94 | Sponsor Protocol Number: 02-2008 | Start Date*: 2009-01-30 | |||||||||||
| Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY | |||||||||||||
| Full Title: Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing After Prior Chemotherapy: a Phase II I.T.M.O. Study | |||||||||||||
| Medical condition: Patients affected by biliary tract cancer progressing after prior chemotherapy | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001224-19 | Sponsor Protocol Number: 1/0196/16 | Start Date*: 2019-02-11 | ||||||||||||||||||||||||||
| Sponsor Name:Lekárska fakulta Univerzity Komenského v Bratislave | ||||||||||||||||||||||||||||
| Full Title: Non-invasive in-vivo prediction of therapeutic response to inhibitors of angiogenesis using gallium (68Ga) NODAGA-RGD PET/CT | ||||||||||||||||||||||||||||
| Medical condition: Advanced metastatic cancer of the colon or rectum | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: SK (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2005-005661-11 | Sponsor Protocol Number: XELOXART | Start Date*: 2006-03-30 | |||||||||||
| Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO" | |||||||||||||
| Full Title: PHASE II STUDY OF NEOADJUVANT CHEMORADIOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER | |||||||||||||
| Medical condition: rectal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-019740-39 | Sponsor Protocol Number: COMEDIANS | Start Date*: 2010-04-26 | |||||||||||
| Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI | |||||||||||||
| Full Title: Isotonic contrast (iodixanol) administration vs. low osmolar contrast (iopromide) use: evaluating risk of contrast-induced nephropathy in cancer patients at very low risk | |||||||||||||
| Medical condition: Oncological patients undergoing to diagnostic imaging | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-005087-14 | Sponsor Protocol Number: CPP-401 | Start Date*: 2008-11-12 | ||||||||||||||||
| Sponsor Name:Centre Paul Papin | ||||||||||||||||||
| Full Title: Comparison of 2 morphine administration’s mode using Pump IntraThecal (IDDS)for Analgesia in patients with Cancer pain, resistant to conventional antalgic treatment | ||||||||||||||||||
| Medical condition: Patients with intractable cancer pain, either uncontrolled with standard analgesia , or undergoing severe side effects due to analgesia . Patients undergo implantation of a Medtronic intrathecal pu... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2007-003048-31 | Sponsor Protocol Number: P070404 | Start Date*: 2007-10-10 | |||||||||||
| Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
| Full Title: Etude de phase II du sunitinib ( SUTENT®) pour le traitement de patients atteints de cancer de la prostate hormono-résistant après progression sous docétaxel. | |||||||||||||
| Medical condition: -Patients présentant un cancer de la prostate métastatique hormono-résistant en progression après une 1ère ligne de traitement par docétaxel. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-002470-40 | Sponsor Protocol Number: PROSORA | Start Date*: 2017-11-16 |
| Sponsor Name:Erasmus MC Cancer Institute | ||
| Full Title: Observational study of the effects of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib (PROSORA-study) | ||
| Medical condition: patients with unresectable hepatocellular cancer, advanced clear-cell renal cell carcinoma, locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-003814-14 | Sponsor Protocol Number: ML19498 | Start Date*: 2006-03-13 |
| Sponsor Name:Unidad Integral de Investigación en Oncología, S.L. | ||
| Full Title: Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neck | ||
| Medical condition: Mestastatic or locally advanced Epidermoid carcinoma of the head and neck | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2007-002886-11 | Sponsor Protocol Number: BEBYP | Start Date*: 2008-01-14 | |||||||||||
| Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST | |||||||||||||
| Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLU... | |||||||||||||
| Medical condition: METASTATIC COLORECTAL CANCER PATIENTS | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-018491-24 | Sponsor Protocol Number: 31295 | Start Date*: 2010-07-15 | |||||||||||
| Sponsor Name:Vrije Universiteit Medical Center | |||||||||||||
| Full Title: Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells | |||||||||||||
| Medical condition: patients with malignant bone metastases | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-021962-31 | Sponsor Protocol Number: Protocolversion1-20100713 | Start Date*: 2011-10-06 | |||||||||||
| Sponsor Name:Bo Lennernäs | |||||||||||||
| Full Title: KEES- A single arm phase II trial of the peroral regimen KEES (Ketokonazole, Etoposide, Estramustine, Sendoxan) in patients with Castration Resistant Prostate Cancer (CRPC) | |||||||||||||
| Medical condition: Men with castration resistant prostate cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: SE (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-001332-35 | Sponsor Protocol Number: AX-CL-PANC-PI-0006859 | Start Date*: 2017-03-20 |
| Sponsor Name:Academic Medical Center Amsterdam | ||
| Full Title: A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer | ||
| Medical condition: Locally advanced pancreatic adenocarcinoma without distant metastases, according to the Dutch Pancreatic Cancer Group (DPCG) definition. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-001369-27 | Sponsor Protocol Number: PACLIDOX 07 | Start Date*: 2008-02-12 | |||||||||||
| Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE | |||||||||||||
| Full Title: PHASE II STUDY OF LIPOSOME-ENCAPSULATED DOXORUBICIN PLUS PACLITAXEL AND TRASTUZUMAB AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY-ADVANCED BREAST CANCER | |||||||||||||
| Medical condition: Operable breast cancer patients (T>2 cm, cT2-3, N0-N2, M0) or potentially operable, locally advanced breast cancer patients (T4, N0-2, M0) or inflammatory breast cancer patients (T4d, N0-2, M0), wi... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-005431-86 | Sponsor Protocol Number: FuTuRe | Start Date*: 2014-02-10 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide. | ||
| Medical condition: Castration-resistant prostate cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-003189-29 | Sponsor Protocol Number: ONCO-01-2017 | Start Date*: 2018-02-09 | |||||||||||
| Sponsor Name:L'Institut Mutualiste Montsouris | |||||||||||||
| Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer | |||||||||||||
| Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-001428-23 | Sponsor Protocol Number: M17GEL | Start Date*: 2017-09-29 | |||||||||||
| Sponsor Name:NKI-AVL | |||||||||||||
| Full Title: AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trial | |||||||||||||
| Medical condition: breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-002480-94 | Sponsor Protocol Number: 69HCL17_0342 | Start Date*: 2021-07-21 | |||||||||||
| Sponsor Name:Hospices Civils de Lyon | |||||||||||||
| Full Title: Assessment of cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in first or secondary platinum-resistant recurrent ovarian epithelial cancer. HIPOVA-01 | |||||||||||||
| Medical condition: Patients with First or second recurrence of platin-resistant epithelial ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-006410-36 | Sponsor Protocol Number: BORT-112 | Start Date*: 2022-05-26 | ||||||||||||||||||||||||||
| Sponsor Name:Clínica Universidad Navarra | ||||||||||||||||||||||||||||
| Full Title: Phase Ib/II open-label clinical study of intratumoral administration of BO-112 in combination with radiotherapy and nivolumab in patients with metastatic PD-1/PDL-1 refractory non-small cell lung c... | ||||||||||||||||||||||||||||
| Medical condition: Metastatic PD-1/PDL-1 refractory non-small-cell lung cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.